Carlos E. Salazar-Mejía, Servicio de Oncología, Centro Universitario Contra el Cáncer, Hospital Universitario “Dr. José Eleuterio González”, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Javier A. Martínez-Moyano, Oncology Service, Centro Universitario Contra el Cáncer, “Dr. José Eleuterio González” University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Hugo E. Solis-Lara, Department of Radiology, Centro Universitario de Imagen Diagnóstica, “Dr. José Eleuterio González” University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Eduardo J. Cantú-Casas, Department of Radiology, Doctors Hospital East, Guadalupe, Nuevo León, México
Frida Valle-Domínguez, Oncology Service, Centro Universitario Contra el Cáncer, “Dr. José Eleuterio González” University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Valeria S. Narvaez-Gonzalez, Oncology Service, Centro Universitario Contra el Cáncer, “Dr. José Eleuterio González” University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Oscar Vidal-Gutiérrez, Autonomous University of Nuevo Leon, School of Medicine and “Dr. José Eleuterio González” University Hospital; Oncology Service at the University Center against Cancer (CUCC by its Spanish acronym). Monterrey, Nuevo León, Mexico
David Hernández-Barajas, Oncology Service, Centro Universitario Contra el Cáncer, “Dr. José Eleuterio González” University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
We present the case of a 68-year-old man with a recurrence of a high-grade leiomyosarcoma with metastatic disease. Despite initial treatment with liposomal doxorubicin, disease progression was observed after three cycles. A molecular study revealed an activating mutation of the RET gene, and treatment with cabozantinib was started at a dose of 60 mg daily. Five months later, the patient had a partial metabolic response. However, disease progression was documented two months later, and treatment was suspended. This case highlights the clinical activity of cabozantinib as monotherapy after failure of first-line chemotherapy in recurrent high-grade leiomyosarcoma with RET gene mutation.
Palabras clave: Leiomyosarcoma. Metastatic. Recurrent. RET mutation. Cabozantinib. Case report.